search
Back to results

The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients

Primary Purpose

Gout

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Allopurinol
Sponsored by
Hillel Yaffe Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gout

Eligibility Criteria

25 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Gout patients

Exclusion Criteria:

  • Pregnant women
  • Chronic renal failure
  • Patients with Allopurinal hypersensitivity

Sites / Locations

  • Hillel Yaffe Medical Center

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Gout Patients

Arm Description

Allopurinol 100 mg-300mg/day as secondary treatment in gout patients

Outcomes

Primary Outcome Measures

Gout patients treated with Allopurinol
Retrospective identification through medical records of percentage of gout patients treated with Allopurinol

Secondary Outcome Measures

Patients with contraindication to Allopurinol
Retrospective identification through medical records of percentage of gout patients with contraindications to Allopurinol

Full Information

First Posted
July 18, 2018
Last Updated
July 18, 2018
Sponsor
Hillel Yaffe Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03601260
Brief Title
The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients
Official Title
To Examine the Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients as Secondary Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Unknown status
Study Start Date
August 2018 (Anticipated)
Primary Completion Date
December 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hillel Yaffe Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the study is to determine the percentage of cases of acute treatment with Allopurinol in gout patients who have been previously treated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gout

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
700 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Gout Patients
Arm Type
Other
Arm Description
Allopurinol 100 mg-300mg/day as secondary treatment in gout patients
Intervention Type
Drug
Intervention Name(s)
Allopurinol
Intervention Description
Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
Primary Outcome Measure Information:
Title
Gout patients treated with Allopurinol
Description
Retrospective identification through medical records of percentage of gout patients treated with Allopurinol
Time Frame
Six months
Secondary Outcome Measure Information:
Title
Patients with contraindication to Allopurinol
Description
Retrospective identification through medical records of percentage of gout patients with contraindications to Allopurinol
Time Frame
Six months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Gout patients Exclusion Criteria: Pregnant women Chronic renal failure Patients with Allopurinal hypersensitivity
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fadi Khalaila, MD
Phone
972-52-3326629
Email
khalailaf@yahoo.com
Facility Information:
Facility Name
Hillel Yaffe Medical Center
City
Hadera
ZIP/Postal Code
38100
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fadi Khalaila, MD
Phone
972-52-3326629
Email
khalailaf@yahoo.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients

We'll reach out to this number within 24 hrs